Candida Bloodstream Infections in Italy: Changing Epidemiology during 16 Years of Surveillance
Table 3
Risk analysis of death with a univariate logistic mode.
Death
Living
(Wald test)
Age, years (median, I and III quartile)
58.0 (44.0–74.0)
42.0 (8.0–64.0)
<0.0001
Gender, (%)
Male
72 (64.9)
187 (66.1)
0.819
Female
39 (35.1)
96 (33.9)
Catheter, . (%)
Yes
99 (89.2)
241 (85.2)
0.128
No
12 (10.8)
42 (14.8)
Antibiotic therapy, . (%)
Yes
97 (87.4)
245 (86.6)
0.830
No
14 (12.6)
38 (13.4)
Antifungal prophylaxis, . (%)
Yes
36 (32.4)
87 (30.7)
0.745
No
75 (67.6)
196 (69.3)
Candida species, . (%)
C. albicans
48 (43.2)
126 (44.5)
0.001
C. parapsilosis
24 (21.6)
113 (9.9)
C. glabrata
11 (9.9)
11 (3.9)
C. guilliermondii
7 (6.3)
12 (4.2)
C. tropicalis
8 (7.2)
11 (3.9)
C. krusei
6 (5.4)
5 (1.8)
Other
7 (6.3)
5 (1.8)
Department, . (%)
Adult oncohaematology
5 (4.5)
18 (6.4)
<0.001
Pediatric oncohaematology
—
49 (17.3)
NICU
12 (10.8)
54 (19.1)
ICU
58 (52.2)
65 (23)
General surgery
12 (10.8)
45 (15.9)
General internal medicine
17 (15.3)
43 (15.2)
Specialist surgery
7 (6.3)
8 (2.8)
NICU: neonatal intensive care unit. ICU: intensive care unit. Wilcoxon test. The pediatric haematology patients were excluded from analysis because none of the candidemic patients died.
